<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>02873nam a2200301   4500</leader>
  <controlfield tag="001">ESSALUD</controlfield>
  <controlfield tag="005">20260805113858.0</controlfield>
  <controlfield tag="007">ta</controlfield>
  <controlfield tag="008">      t        pe ||||| |||| 00| 0 spa d</controlfield>
  <datafield tag="040" ind1=" " ind2=" ">
    <subfield code="a">BMG</subfield>
  </datafield>
  <datafield tag="041" ind1=" " ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Gharahdaghi, Nima </subfield>
    <subfield code="e">Autor</subfield>
    <subfield code="9">53934</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Interleukin-10 autoantibodies and HLA-DRB1*01:03 in inflammatory bowel disease</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">p&#xE1;ginas: 2212-2222</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">Background: Neutralizing autoantibodies against interleukin-10 can result in a phenocopy of monogenic defects of interleukin-10 signaling in children and may be associated with inflammatory bowel disease (IBD). The allele HLA-DRB1*01:03 is the strongest genetic risk factor for ulcerative colitis.
Methods: We used a cellular interleukin-10 reporter assay and a confirmatory competitive enzyme-linked immunosorbent assay to assess neutralizing interleukin-10 autoantibodies in serum samples obtained from patients with IBD in the Oxford and U.K. IBD BioResource cohorts and from persons without IBD (controls). An in vitro cytokine-release bioassay was performed in a subgroup of patients to assess interleukin-10, interleukin-23, interleukin-1&#x3B2;, tumor necrosis factor, and interleukin-6. We performed HLA association analysis using imputation and high-resolution sequencing.
Results: Interleukin-10&#x2013;neutralizing autoantibodies were detected in 173 of 4909 patients with IBD (3.5%; 95% confidence interval [CI], 3.0 to 4.1) and in none of 1006 controls (P&lt;0.001). High anti&#x2013;interleukin-10 activity in serum was associated with a reduction in detectable interleukin-10 and with an exaggerated proinflammatory cytokine response, consistent with functional neutralization of interleukin-10 signaling. Anti&#x2013;interleukin-10 seropositivity was strongly associated with HLA-DRB1*01:03 on the basis of imputed data from the Oxford cohort (odds ratio, 50.0; 95% CI, 16.4 to 152.3; P=6.14&#xD7;10&#x2212;12) and the U.K. IBD BioResource cohort (odds ratio, 24.7; 95% CI, 14.5 to 42.1; P=6.20&#xD7;10&#x2212;32) and in a high-resolution sequencing analysis of data from the Oxford cohort (odds ratio, 29.5; 95% CI, 12.2 to 71.1; P=4.85&#xD7;10&#x2212;14).
Conclusions: Neutralizing interleukin-10 autoantibodies were present in a subgroup of patients with IBD and were strongly associated with HLA-DRB1*01:03.
</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">ALERGIA</subfield>
    <subfield code="9">7055</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">ENFERMEDAD AUTOINMUNE</subfield>
    <subfield code="9">53665</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">GENETICA</subfield>
    <subfield code="9">1105</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">GASTROENTEROLOG&#xCD;A</subfield>
    <subfield code="9">12562</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">ENFERMEDAD INFLAMATORIA INTESTINAL</subfield>
    <subfield code="9">53935</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Yeh, Pai-Jui </subfield>
    <subfield code="9">53936</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Cer&#xF3;n-Guti&#xE9;rrez, Lourdes  </subfield>
    <subfield code="9">53937</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Griffin, Helen  </subfield>
    <subfield code="9">53938</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Gordon, Hannah </subfield>
    <subfield code="9">53939</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Jayamanne,  Chamara</subfield>
    <subfield code="9">53940</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
    <subfield code="0">22717</subfield>
    <subfield code="9">22641</subfield>
    <subfield code="d">Massachusetts NEJM Group</subfield>
    <subfield code="o">NEJM008</subfield>
    <subfield code="t">The New England Journal of Medicine </subfield>
    <subfield code="w">ESSALUD</subfield>
    <subfield code="x">0028-4793</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="c">ARTICULOS</subfield>
    <subfield code="e">2026-08-03</subfield>
    <subfield code="z">SQB</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">22776</subfield>
    <subfield code="d">22776</subfield>
  </datafield>
</record>
